NephKey focuses on immuno-renal orphan indications in children, particularly pediatric nephrotic syndrome, which affects over 30,000 patients in the US. We are pursuing a path to approval with a potential registrational study within 2 years.The FDA has recognized the severe unmet need for approved therapies to treat this condition and actively supports NephKey's efforts. The lead compound is de-risked, with new composition-of-matter patent life.